Arena Pharma (ARNA) Misses Q4 EPS by 25c

Arena Pharma (NASDAQ: ARNA) reported Q4 EPS of ($2.10), $0.25 worse than the analyst estimate of ($1.85). Revenue for the quarter came in at $37 thousand versus the consensus estimate of $560 thousand.

“This quarter we were pleased to announce the completion of enrollment of the ELEVATE UC 52 trial for etrasimod and expansion of our cardiovascular franchise to include temanogrel. Our growing and diverse pipeline is supported by a strong cash position,” said Amit D. Munshi, President and CEO of Arena. “Adapting to the impact of the global COVID-19 pandemic, our team has continued to put safety of trial participants first while striving to maintain important momentum across our programs.”

For earnings history and earnings-related data on Arena Pharma (ARNA) click here.

You May Also Be Interested In

• Humana soars, Alignment Healthcare sinks on Medicare rating changes
• Helen of Troy (HELE) Tops Q2 EPS by 28c, Misses on Revenue; Offers FY27 Guidance
• PepsiCo (PEP) Tops Q3 EPS by 4c, cuts EPS forecast